JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 19, 2006; DOI: 10.1124/jpet.106.107144


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.107144v1
jpet.106.107144v2
318/3/1020    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, D.
Right arrow Articles by Porter, T. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, D.
Right arrow Articles by Porter, T. D
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL


Received for publication May 2, 2006.
Revised May 18, 2006.
Accepted for publication May 18, 2006.

Policosanol Inhibits Cholesterol Synthesis in Hepatoma Cells by Activation of AMP-kinase

Dev Singh 1, Li Li 1, Todd D Porter 1*

1 University of Kentucky

* Address correspondence to: E-mail: tporter{at}uky.edu

Abstract

Policosanol is a mixture of long-chain primary alcohols that has been shown to decrease serum cholesterol in animals and in man. The hypocholesterolemic effect appears to result from a decrease in cholesterol synthesis by suppression of HMG-CoA reductase activity, but the mechanism of this suppression and the active components of policosanol have not been established. In the present study we investigated the ability of policosanol and its principal components to inhibit cholesterol synthesis in cultured rat hepatoma cells. Maximal inhibition by policosanol yielded a 30% decrease in 14C-acetate incorporation without evidence of cellular toxicity. Octacosanol (C28, the major constituent of policosanol), heptacosanol (C27), and hexacosanol (C26) yielded smaller and statistically insignificant decreases in cholesterol synthesis, whereas triacontanol (1-hydroxytriacontane, C30) replicated the inhibition obtained with policosanol. At pharmacologic concentrations (<5 µg/ml) policosanol and triacontanol decreased 14C-acetate incorporation into cholesterol without affecting the incorporation of 14C-mevalonate, indicating that these compounds act at or above HMG-CoA reductase. Policosanol and triacontanol did not directly inhibit HMG-CoA reductase, and incubation of these compounds with hepatoma cells did not affect reductase enzyme levels. However, reductase activity was decreased by up to 55% in lysates prepared from these cells, suggesting that HMG-CoA reductase activity was down-regulated by policosanol treatment. Consistent with this hypothesis, a three-fold increase in AMP-kinase phosphorylation was noted in policosanol-treated cells. As AMP-kinase is activated by phosphorylation and is well established to suppress HMG-CoA reductase activity, these results suggest that policosanol or a metabolite decreases HMG-CoA reductase activity by activating AMP-kinase.


Key words: AMP kinase, HMG CoA reductase, cell culture, cholesterol synthesis, metformin, policosanol


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
S. P. J. Dullens, R. P. Mensink, M. C. E. Bragt, A. K. Kies, and J. Plat
Effects of emulsified policosanols with different chain lengths on cholesterol metabolism in heterozygous LDL receptor-deficient mice
J. Lipid Res., April 1, 2008; 49(4): 790 - 796.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.